Aptorum Group Ltd Class A Total Assets
Aptorum Group Ltd Class A total assets. Based on the latest financial reports, Aptorum Group Ltd Class A (APM) holds total assets worth $17.13 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see APM stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Aptorum Group Ltd Class A (2016–2025)
Total assets of Aptorum Group Ltd Class A from 2016 to 2025. This chart illustrates how Aptorum Group Ltd Class A's total assets have evolved over time, based on quarterly financial data. See APM stock price and chart for real-time trading data and today's change.
Aptorum Group Ltd Class A - Asset Composition Analysis
Aptorum Group Ltd Class A Total Assets Breakdown (December 2025)
Aptorum Group Ltd Class A total assets breakdown as of December 2025. Aptorum Group Ltd Class A's total assets of $17.13 Million consist of 19.2% current assets and 80.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Aptorum Group Ltd Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore APM working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aptorum Group Ltd Class A's current assets represent 19.2% of total assets in 2025, an increase from 1.6% in 2016.
- Cash Position: Cash and equivalents constituted 18.5% of total assets in 2025, up from 1.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Aptorum Group Ltd Class A Competitors by Total Assets
Key competitors of Aptorum Group Ltd Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Aptorum Group Ltd Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.45 | 0.22 | 5.40 |
| Quick Ratio | 0.45 | 0.22 | 5.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.48 Million | $-3.38 Million | $17.86 Million |
Aptorum Group Ltd Class A - Advanced Valuation Insights
This section examines the relationship between Aptorum Group Ltd Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.28 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 15.9% |
| Total Assets | $18.69 Million |
| Market Capitalization | $570.06K USD |
Valuation Analysis
Below Book Valuation: The market values Aptorum Group Ltd Class A's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Aptorum Group Ltd Class A's assets grew by 15.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Aptorum Group Ltd Class A (2016–2025)
The table below shows the annual total assets of Aptorum Group Ltd Class A from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $18.69 Million | +15.88% |
| 2024-12-31 | $16.13 Million | -21.85% |
| 2023-12-31 | $20.64 Million | -1.09% |
| 2022-12-31 | $20.87 Million | -4.75% |
| 2021-12-31 | $21.91 Million | -50.47% |
| 2020-12-31 | $44.23 Million | +84.65% |
| 2019-12-31 | $23.95 Million | -46.86% |
| 2018-12-31 | $45.07 Million | +42.82% |
| 2017-12-31 | $31.56 Million | +24.33% |
| 2016-12-31 | $25.38 Million | -- |
About Aptorum Group Ltd Class A
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small mol… Read more